Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 24,245

Document Document Title
WO/2019/053425A1
There is herein provided a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X, R1, ring A, m and n have meanings as provided in the description.  
WO/2019/055590A1
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therape...  
WO/2019/044739A1
A phosphor which is composed of a maleimide compound represented by general formula (1). (In the formula, R1 represents a hydrogen atom, an alkyl group having 1-6 carbon atoms or a halogen atom; A represents a substituted or unsubstitute...  
WO/2019/042267A1
Disclosed in the present invention are a pyrrole-2-formamide compound, a preparation method therefor, a pharmaceutical composition thereof, and application thereof in the preparation of drugs for treating or preventing infective diseases...  
WO/2019/042447A1
A novel toxin and a method for preparing an intermediate thereof. Specifically provided are a compound as represented by formula (III) and a method for preparing same, and a method for preparing a compound as represented by formula (I) w...  
WO/2019/042301A1
The present invention provides a new class of (E)-α,β-unsaturated amide compounds represented by formula I, and also relates to methods for preparing such compounds and the pharmaceutical uses thereof. The compounds have the effect of ...  
WO/2019/040105A2
The present disclosure relates to compounds according to Formula (I), treating diseases.  
WO/2019/040106A2
The present disclosure relates to compounds according to Formulae disclosed herein, useful for treating diseases.  
WO/2019/040869A1
This invention relates to compounds for treating a protozoan parasitic infection and to pharmaceutical compositions comprising the compounds; and to methods of using the compounds and compositions to treat parasitic infections.  
WO/2019/033330A1
Compounds of Formula (I) a or (I) b: including certain quinone derivatives, and the corresponding pharmaceutical compositions, which may serve to modulate ferroptosis in a subject. Also disclosed herein are the preparations of these comp...  
WO/2019/033219A1
A class of compounds useful in pharmaceutical compositions and methods for treating or preventing cancer is described. Analogs of Mycalolide B have been prepared and tested in breast and ovarian cancer cell lines. The compounds show util...  
WO/2019/033590A1
Disclosed are a substituted benzoyl cyclohexanedione compound or a tautomer and salt thereof, a preparation method therefor, a herbicidal composition and the use. The substituted benzoyl cyclohexanedione compound or a tautomer and salt t...  
WO/2019/033773A1
The present invention is directed to tetramaleimide linkers and use thereof, more specifically to the compounds represented by formula I and their use in the preparation of antibody-drug conjugates (ADCs). The ADCs obtained from the tetr...  
WO/2019/029598A1
A preparing method for high-purity levetiracetam, comprising: adjusting the pH of an extracted aqueous layer obtained by dissociating (S)-α-2-oxo-1-pyrrolidineacetic acid (R)- methylbenzylamine salt to 5-9; removing water; adding an org...  
WO/2019/029211A1
Disclosed by the present invention are an SIRT6 small-molecule allosteric activator and the application thereof, and provided is an SIRT6 small-molecule allosteric activator that contains a derivative as shown in formula (1) or a pharmac...  
WO/2019/029274A1
Provided in the present invention are a novel compound and a preparation method therefor. The general structural formula of the compound is shown as formula I. Animal experiments prove that the compound of the present invention has the e...  
WO/2019/029273A1
A novel compound, a preparation method therefor and use thereof. The structure is as shown in formula I. Said compound can be used for preparing medicaments for treating diseases such as Alzheimer's disease, Parkinson's disease, vascular...  
WO/2019/032632A1
Disclosed are compounds of Formula (I): (I) or a salt thereof, wherein: X is -CH2- or -C(O)-; R1 is -OH or -OP(O)(OH)2; L is a bond, -CH2-, or -C(O)-; R2 is n-C6-8 alkyl; each R3 is independently selected from Cl and -CH3; and n is zero,...  
WO/2019/030158A1
The present invention relates to cocrystalsof2-[(1R,6R)-6-isopropenyl-3-methylcyclohex- 2-en-1-yl]-5-pentylbenzene-1,3-diol and a zwitterion coformer, processes for their preparation, and their use as a medicament and for the purificatio...  
WO/2019/028666A1
Disclosed is a method for preparing levetiracetam, comprising the following steps: performing resolution under the action of an ester hydrolase using 2-halobutyrate as a raw material to obtain (S)-2-halobutyrate, reacting with 2-pyrrolid...  
WO/2019/028669A1
The present invention relates to a method for preparing levetiracetam, characterized by performing ammonolysis with liquid ammonia using (S)-α-ethyl-2-oxo-1-pyrrolidine acetate as a raw material under a solvent-free condition to obtain ...  
WO/2019/028671A1
Provides is a method for preparing levetiracetam. The method comprises producing (R/S)-α-ethyl-2-oxo-1-pyrrolidine acetate under the action of an alkaline reagent using 2-bromobutyrate and 2-pyrrolidinone as raw materials, performing re...  
WO/2019/032631A1
Disclosed are compounds of Formula (I): (I) or a salt thereof, wherein: X is CH or N; Y is CH or N; R1 is -OH or -OP(O)(OH)2; L1 is -CR3=N-O-CRaRa- or CRaR-O-N=CR3; L2 is a bond, -C(O)-, or S(O)2-;and R2, R3, Ra, m, and n are defined her...  
WO/2019/028117A1
Provided herein are resins, or compounds, embraced by structure (I): where L is a covalent bond, a hydrocarbylene linker optionally having one or more hetero atoms, with or without any one or more of urethanes, ureas, amides, carbamoyls,...  
WO/2019/028168A1
Materials and methods for generating protein-polymer conjugates on solid supports are provided herein. The methods can include, for example, reversibly immobilizing a protein on a solid support, modifying the protein by adding polymer su...  
WO/2019/025156A1
Described are substituted pyrrolidinones of general formula (I) and the use thereof as herbicides, in particular for controlling weeds and/or weed grasses in crop cultivation and/or as plant growth regulators for influencing the growth o...  
WO/2019/028228A1
Processes for preparing 5,5-dimethyl-3-methylenepyrrolidin-2-one, (S)-3,5,5-trimethylpyrrolidine-2-one, (R)-3,5,5-trimethylpyrrolidine-2-one, (S)-2,4,4-trimethylpyrrolidine, and (R)-2,4,4-trimethylpyrrolidine, and their salt forms are di...  
WO/2019/027003A1
The present invention provides a heterocyclic compound having orexin receptor type 2 agonist activity. In the present invention, a compound represented by formula (I) (in the formula, each symbol is as described in the specification) or ...  
WO/2019/023147A1
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured.The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, c...  
WO/2019/021608A1
The compound according to the present invention is represented by formula (1) [in formula (1), R1 is a C1-3 linear or branched alkyl group or a hydroxyl group; R2 is a 1-pyrrolyl group, a 2-pyrrolyl group, or a 3-pyrrolyl group]. The pre...  
WO/2019/023145A1
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured. The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, ...  
WO/2019/020726A1
The invention discloses a method for preparation of alkylated, fluoro alkylated, chloro alkylated and fluorochloro alkylated compounds by a heterogeneous Co-catalysed alkylation or fluoro, chloro and fluorochloro alkylation with alkyl ha...  
WO/2019/022426A1
The present invention relates to a method for preparing N-substituted maleimide and, more particularly, to a method for preparing N-substituted maleimide, comprising the steps of: a) reacting maleic anhydride with a primary amine in the ...  
WO/2019/023453A1
The disclosed and/or claimed inventive concept(s) provides a complex of at least one halogen and a compound comprising at least one ether, thioether, and/or imine moiety and at least two lactam moieties. The disclosed and/or claimed inve...  
WO/2019/021290A1
This invention is directed to a process for the preparation of glycopyrrolate tosylate comprising the step of reacting a halogen salt of glycopyrrolate with tosylic acid or a salt thereof in the presence of hydrogen peroxide and at least...  
WO/2019/023553A1
The present disclosure relates to bifunctional compounds, which find utility to degrade (and inhibit) Androgen Receptor. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to ...  
WO/2019/016745A1
Aspects of the present application relate to process for the preparation of Pyrrolidine derivatives useful as key intermediates for active ingredients. Specific aspects relate to alternate process for the preparation of Upadacitinib inte...  
WO/2019/018592A3
The invention generally relates to an improved process for the preparation of N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyra zolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cy clohexyl)acetamide, as well as novel ...  
WO/2019/016269A1
The present invention relates to derivatives of formula (I) which bind to the liver X receptor (LXRα and/or LXRβ) and act preferably as inverse agonists of LXR.  
WO/2019/008506A1
The invention is directed to substituted bridged cycloalkane derivatives. Specifically, the invention is directed to compounds according to Formula (I) wherein X, a, b, C, D, L2, L3, Y1, Y2, R2, R4, R5, R6, z2, z4, z5, and z6 are as defi...  
WO/2019/009412A1
The present invention addresses the problem of providing a novel compound having high LSD1 inhibitory activity, high selectivity for LSD1 inhibition, and/or having useful therapeutic effects for various diseases. One embodiment of the pr...  
WO/2019/007889A1
The invention relates to a method for improving the utilization of the production potential of transgenic plants by treating the plant with an effective amount of the compound of formula (la) as described herein.  
WO/2019/009317A1
Provided are: a novel compound usable as an organic tag which has a high stability under acidic conditions in peptide synthesis, etc.; and a method for highly efficiently producing a peptide wherein the compound is used as an organic tag.  
WO/2019/008025A1
The present invention relates to compounds of formula (I) wherein Q is selected from O or S; R1 is a non-aromatic heterocyclic group comprising at least one ring nitrogen atom, wherein R1 is attached to the sulfur atom of the sulfonylure...  
WO/2019/008595A1
The present invention relates to an efficient process for the preparation of 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1- methylpiperidin-4-yl)urea and pharmaceutically acceptable salts thereof involving use of novel intermediates.  
WO/2019/002571A1
This invention relates to compounds of formula (I) and their use as allosteric modulators of mGluR5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment and/or prev...  
WO/2019/002344A1
The invention discloses a method for preparation of alpha-methyl-L-proline starting from proline and comprising three steps, first a conversion with chloral, then a conversion with methyl bromide and then a conversion with aqueous HCl.  
WO/2019/006074A1
Disclosed are P2X7 receptor ligands having the formula (I) in which R = -(CH2)n-(O-CH2CH2)m-Ol-(CH2)p-X, l= 0-1, m = 0-6, n = 2-3, p = 0-2, and X = Br, CI, F or 18F. In illustrative embodiments, R = -(CH2)n, and n = 2-3. The receptor lig...  
WO/2019/003573A1
The present invention provides a compound represented by formula (1) (in formula (1), R1 and R2 each independently represent a group represented by formula (2) or NHR0 (where R1 and R2 are not simultaneously NHR0), R0 represents any one ...  
WO/2018/235966A1
The present invention provides a compound which has an excellent inhibitory activity on histone acetyltransferase of EP300 and/or CREBBP, or a pharmacologically acceptable salt of the compound. A compound represented by formula (1) or a ...  

Matches 1 - 50 out of 24,245